A recent European study concluded that bevacizumab was more cost-effective than ranibizumab or aflibercept for treatment of AMD.[22] Although we were not able to evaluate cost-effectiveness, bevacizumab was used more commonly than other anti-VEGF agents in our study, likely due to its lower cost and previously described efficacy.[23]. This evidence concerns the gene VEGFA and age-related macular degeneration.